A randomized controlled trial of sequential pegylated interferon-α and telbivudine or vice versa for 48 weeks in hepatitis B e antigen-negative chronic hepatitis B

Antiviral Therapy

Volumn 18, Issue 1, 2013, Pages 57-64

  Piccolo, Paola ^a,b   Lenci, Ilaria ^a   Di Paolo, Daniele ^a   Demelia, Luigi ^c   Sorbello, Orazio ^c   Nosotti, Lorenzo ^d   Angelico, Mario ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b FATEBENEFRATELLI HOSPITAL   (Italy)

^c DEPARTMENT OF RADIOLOGY   (Italy)

^d ISTITUTO SUPERIORE DI SANITÀ   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; CREATINE KINASE; HEPATITIS B(E) ANTIGEN; PEGINTERFERON ALPHA; PEGINTERFERON ALPHA2A; TELBIVUDINE; VIRUS DNA;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL THERAPY; ARTICLE; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; MALE; MYALGIA; NEUTROPENIA; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; SEQUENTIAL ANALYSIS; SIDE EFFECT; TREATMENT DURATION; TREATMENT RESPONSE;

ADULT; ALANINE TRANSAMINASE; ANTIVIRAL AGENTS; DNA, VIRAL; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS B E ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; INTERFERON-ALPHA; ITALY; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; THYMIDINE; TREATMENT OUTCOME;

EID: 84874409011     PISSN: 13596535     EISSN: 20402058     Source Type: Journal    
DOI: 10.3851/IMP2281     Document Type: Article

References (32)

1. Alter MJ. Epidemiology and prevention of hepatitis B. Semin Liver Dis 2003; 23:39-46.
2. Kao JH, Chen DS. Global control of hepatitis B virus infection. Lancet Infect Dis 2002; 2:395-403.
3. Lavanchy D. Worldwide epidemiology of HBV infection, disease burden, and vaccine prevention. J Clin Virol 2005; 34 Suppl 1:S1-S3.
4. Custer B, Sullivan SD, Hazlet TK, Iloeje U, Veenstra DL, Kowdley KV. Global epidemiology of hepatitis B virus. J Clin Gastroenterol 2004; 38 Suppl 3:S158-S168.
5. World Health Organization. Introduction of hepatitis B vaccine into childhood immunization services. Geneva: WHO 2001.
6. Burra P, Smedile A, Angelico M, Ascione A, Rizzetto M. Liver transplantation in Italy: Current status. Study Group on Liver Transplantation of the Italian Association for the Study of the Liver (AISF). Dig Liver Dis 2000; 32:249-256.
7. Angelico M, Cillo U, Fagiuoli S, et al. Liver Match, a prospective observational cohort study on liver transplantation in Italy: Study design and current practice of donor-recipient matching. Dig Liver Dis 2011; 43:155-164.
8. Piccolo P, Lenci I, Telesca C, et al. Patterns of chronic hepatitis B in Central Italy: A cross-sectional study. Eur J Public Health 2010; 20:711-713.
9. Stroffolini T, Almasio PL, Sagnelli E, Mele A, Gaeta GB. Evolving clinical landscape of chronic hepatitis B: A multicenter Italian study. J Med Virol 2009; 81:1999-2006.
10. Dal Molin G, Poli A, Crocè LS, et al. C. Hepatitis B virus genotypes, core promoter variants, and precore stop codon variants in patients infected chronically in North-Eastern Italy. J Med Virol 2006; 78:734-740.
11. Enomoto M, Tamori A, Nishiguchi S. Hepatitis B virus genotypes and response to antiviral therapy. Clin Lab 2006; 52:43-47.
12. Erhardt A, Blondin D, Hauck K, et al. Response to interferon alpha is hepatitis B virus genotype dependent: Genotype A is more sensitive to interferon than genotype D. Gut 2005; 54:1009-1013.
13. Brunetto MR, Oliveri F, Colombatto P, Capalbo M, Barbera C, Bonino F. Treatment of chronic anti-HBe-positive hepatitis B with interferon-alpha. J Hepatol 1995; 22:42-44.
14. Brunetto MR, Oliveri F, Coco B, et al. Outcome of anti-HBe positive chronic hepatitis B in alpha-interferon treated and untreated patients: A long term cohort study. J Hepatol 2002; 36:263-270.
15. EASL Clinical Practice Guidelines. Management of Chronic Hepatitis B. J Hepatol 2009; 50:227-242.
16. Lok AS, McMahon BJ. Chronic Hepatitis B: Update 2009. Hepatology 2009; 50:661-662.
17. Carosi G, Rizzetto M. Treatment of chronic hepatitis B: Recommendations from an Italian workshop. Dig Liv Dis 2008; 40:603-617.
18. Hadziyannis SJ, Papatheodoridis GV, Dimou E, Laras A, Papaioannou C. Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B. Hepatology 2000; 32:847-851.
19. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Longterm ttherapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. N Engl J Med 2005; 352:2673-2681.
20. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Longterm therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology 2006; 131:1743-1751.
21. Chang TT, Lai CL, Kew Yoon S, et al. Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology 2010; 51:422-430.
22. Gane EJ, Wang Y, Liaw YF, et al. Efficacy and safety of prolonged 3-year telbivudine treatment in patients with chronic hepatitis B. Liver Int 2011; 31:676-684.
23. Marcellin P, Lau GKK, Bonino F, et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2004; 351:1206-1217.
24. Piccolo P, Lenci I, Demelia L, et al. A randomized controlled trial of pegylated interferon-alpha2a plus adefovir dipivoxil for hepatitis B e antigen-negative chronic hepatitis B. Antivir Ther 2009; 14:1165-1174.
25. Sarin SK, Sood A, Kumar M, et al. Effect of lowering HBV DNA levels by initial antiviral therapy before adding immunomodulator on treatment of chronic hepatitis B. Am J Gastroenterol 2007; 102:96-104.
26. Niro GA, Fontana R, Gioffreda D, et al. Sequential treatment with lamivudine and alpha-interferon in anti-HBe-positive chronic hepatitis B patients: A pilot study. Dig Liver Dis 2007; 39:857-863.
27. Moucari R, Boyer N, Ripault MP, et al. Sequential therapy with adefovir dipivoxil and pegylated Interferon Alfa-2a for HBeAg-negative patients. J Viral Hepat 2011; 18:580-586.
28. Zeuzem S, Gane E, Liaw YF, et al. Baseline characteristics and early on-treatment response predict the outcomes of 2 years of telbivudine treatment of chronic hepatitis B. J Hepatol 2009; 51:11-20.
29. Rijckborst V, Hansen BE, Cakaloglu Y, et al. Early on-treatment prediction of response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B using HBsAg and HBV DNA levels. Hepatology 2010; 52:454-461.
30. Ishak KG. Pathologic features of chronic hepatitis. A review and update. Am J Clin Pathol 2000; 113:40-55.
31. Chen Y, Li X, Ye B, et al. Effect of telbivudine therapy on the cellular immune response in chronic hepatitis B. Antiviral Res 2011; 91:23-31.
32. Wursthorn K, Jung M, Riva A, et al. Kinetics of hepatitis B surface antigen decline during 3 years of telbivudine treatment in hepatitis B e antigen-positive patients. Hepatology 2010; 52:1611-1620.